Abstract
Craniopharyngiomas (CPs) are rare, benign tumors derived from Rathke’s pouch, known for their high recurrence rates and associated morbidity and mortality. Despite significant investigation on risk factors for recurrence, a lack of consensus persists. Recent research suggests that specific histopathological and molecular characteristics are prognostic for disease progression. In this systematic review, we analyzed and consolidated key features of CPs that contribute to increased recurrence rates. This systematic review was performed in accordance with PRISMA guidelines. A search string was created with the keywords “craniopharyngioma,” “histology,” “histopathology,” “molecular,” and “recurrence.” Literature was collected from 2006 to 2016 on the PubMed/Medline and Web of Science databases. The initial search resulted in 242 papers, examined with inclusion and exclusion criteria. The final review included a total of 37 studies, 36 primary studies covering a total of 1461 patients and 1 previous meta-analysis. Cystic lesions and whorl-like arrays were found to be associated with increased recurrence, while previously considered reactive gliosis and finger-shaped protrusions were not. The genetic elements found to be associated with increased risk of recurrence were Ki-67, Ep-CAM, PTTG-1, survivin, and certain RAR isotypes, as well as the glycoproteins osteonectin and chemokines CXCL12/CXCR4. The effects of VEGF, HIF-1α, and p53, despite extensive study, yielded conflicting results. Certain histopathological and molecular characteristics of CPs provide insight into their pathogenesis, likelihood of recurrence, and potential novel targets for therapy.
Similar content being viewed by others
References
Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L (2006) Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol 30:143–150. https://doi.org/10.1080/01913120500408018
Anegawa S, Hayashi T, Nakagawa S, Furukawa Y, Tomokiyo M (2001) Craniopharyngioma with rapid regrowth—role of MIB-1 labeling index. No Shinkei Geka 29:727–733
Bao Y, Peng JX (2016) Origin of craniopharyngiomas: implications for growth pattern, clinical characteristics, and outcomes of tumor recurrence. J Clin Neurosci 125:24–32. https://doi.org/10.3171/2015.6.JNS141883
Bao Y, Qiu BH, Qi ST, Pan J, Lu YT, Peng JX (2016) Influence of previous treatments on repeat surgery for recurrent craniopharyngiomas in children. Childs Nerv Syst 32:485–491. https://doi.org/10.1007/s00381-015-3003-0
Bartlett JR (1971) Craniopharyngiomas. An analysis of some aspects of symptomatology, radiology and histology. Brain J Neurol 94:725–732. https://doi.org/10.1093/brain/94.4.725
Botti G, Scognamiglio G, Marra L, Collina F, Di Bonito M, Cerrone M, Grilli B, Anniciello A, Franco R, Fulciniti F, Ascierto PA, Cantile M (2014) SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression. Virchows Arch 465:331–338. https://doi.org/10.1007/s00428-014-1616-4
Brastianos PK, Santagata S (2016) BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol 174:R139–R144
Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HGW, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JYK, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, Santagata S (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161–U100. https://doi.org/10.1038/ng.2868
Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT, Barker FG (2016) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. JNCI-J Natl Cancer Inst 108:5. https://doi.org/10.1093/jnci/djv310
Burghaus S, Holsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blumcke I, Buslei R (2010) A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch 456:287–300. https://doi.org/10.1007/s00428-009-0873-0
Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, Hahnen E, Kreutzer J, Fahlbusch R (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 109:589–597. https://doi.org/10.1007/s00401-005-1004-x
Cao J, Lin JP, Yang LX, Chen K, Huang ZS (2010) Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas. Br J Neurosurg 24:249–256. https://doi.org/10.3109/02688690903576237
Cavallo LM, Frank G, Cappabianca P, Solari D, Mazzatenta D, Villa A, Zoli M, D'Enza AI, Esposito F, Pasquini E (2014) The endoscopic endonasal approach for the management of craniopharyngiomas: a series of 103 patients. J Neurosurg 121:100–113. https://doi.org/10.3171/2014.3.jns131521
Cermak S, Kosicek M, Mladenovic-Djordjevic A, Smiljanic K, Kanazir S, Hecimovic S (2016) Loss of cathepsin B and L leads to lysosomal dysfunction, NPC-like cholesterol sequestration and accumulation of the key Alzheimer’s proteins. PLoS One 11:17. https://doi.org/10.1371/journal.pone.0167428
Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, Miyasaka A, Kashiyama T, Arimoto T, Kuramoto H, Kawana K, Yano T, Osuga Y, Fujii T (2016) Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Gynecol Oncol 141:564–569. https://doi.org/10.1016/j.ygyno.2016.04.003
Crotty TB, Scheithauer BW, Young WF, Davis DH, Shaw EG, Miller GM, Burger PC (1995) Papillary craniopharyngioma—a clinicopathological study of 48 cases. J Neurosurg 83:206–214. https://doi.org/10.3171/jns.1995.83.2.0206
Cseh B, Doma E, Baccarini M (2014) “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett 588:2398–2406. https://doi.org/10.1016/j.febslet.2014.06.025
Dehdashti AR, Ganna A, Witterick I, Gentili F (2009) Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. Neurosurgery 64:677–687; discussion 687-679. https://doi.org/10.1227/01.neu.0000339121.20101.85
Drimtzias E, Falzon K, Picton S, Jeeva I, Guy D, Nelson O, Simmons I (2014) The ophthalmic natural history of paediatric craniopharyngioma: a long-term review. J Neuro-Oncol 120:651–656. https://doi.org/10.1007/s11060-014-1600-5
Duff JM, Meyer FB, Ilstrup DM, Laws ER, Schleck CD, Scheithauer BW (2000) Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 46:291–302. https://doi.org/10.1097/00006123-200002000-00007
Duo D, Gasverde S, Benech F, Zenga F, Giordana MT (2003) MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis. Clin Neuropathol 22:229–234
Ebrahimi A, Honegger J, Schluesener H, Schittenhelm J (2013) Osteonectin expression in surrounding stroma of craniopharyngiomas: association with recurrence rate and brain infiltration. Int J Surg Pathol 21:591–598. https://doi.org/10.1177/1066896913486695
Garnett MR, Puget S, Grill J, Sainte-Rose C (2007) Craniopharyngioma. Orphanet J Rare Dis 2:18. https://doi.org/10.1186/1750-1172-2-18
Gong J, Zhang HL, Xing SS, Li CD, Ma ZY, Jia G, Hu WN (2014) High expression levels of CXCL12 and CXCR4 predict recurrence of adamantinomatous craniopharyngiomas in children. Cancer Biomark 14:241–251. https://doi.org/10.3233/cbm-140397
Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Mehta VS (2006) Recurrence in craniopharyngiomas: analysis of clinical and histological features. J Clin Neurosci 13:438–442. https://doi.org/10.1016/j.jocn.2005.05.013
Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Sharma BS, Mehta VS (2006) Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features. Childs Nerv Syst 22:50–55. https://doi.org/10.1007/s00381-005-1171-z
Holsken A, Stache C, Schlaffer SM, Flitsch J, Fahlbusch R, Buchfelder M, Buslei R (2014) Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche? Pituitary 17:546–556. https://doi.org/10.1007/s11102-013-0543-8
Hussain I, Eloy JA, Carmel PW, Liu JK (2013) Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies A review. J Neurosurg 119:106–112. https://doi.org/10.3171/2013.3.jns122214
Ishida M, Hotta M, Tsukamura A, Taga T, Kato H, Ohta S, Takeuchi Y, Nakasu S, Okabe H (2010) Malignant transformation in craniopharyngioma after radiation therapy: a case report and review of the literature. Clin Neuropathol 29:2–8
Izumoto S, Suzuki T, Kinoshita M, Hashiba T, Kagawa N, Wada K, Fujimoto Y, Hashimoto N, Saitoh Y, Maruno M, Yoshimine T (2005) Immunohistochemical detection of female sex hormone receptors in craniopharyngiomas: correlation with clinical and histologic features. Surg Neurol 63:520–525. https://doi.org/10.1016/j.surneu.2004.08.094
Kapinas K, Lowther KM, Kessler CB, Tilbury K, Lieberman JR, Tirnauer JS, Campagnola P, Delany AM (2012) Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol 31:299–307. https://doi.org/10.1016/j.matbio.2012.03.002
Kato K, Nakatani Y, Kanno H, Inayama Y, Ijiri R, Nagahara N, Miyake T, Tanaka M, Ito Y, Aida N, Tachibana K, Sekido K, Tanaka Y (2004) Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma. J Pathol 203:814–821. https://doi.org/10.1002/path.1562
Katz EL (1975) Late results of radical excision of craniopharyngiomas in children. J Neurosurg 42:86–93. https://doi.org/10.3171/jns.1975.42.1.0086
Kim S, An SS (2016) Role of p53 isoforms and aggregations in cancer. Medicine 95:e3993. https://doi.org/10.1097/md.0000000000003993
Kim SK, Wang KC, Shin SH, Choe G, Chi JG, Cho BK (2001) Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors. Childs Nerv Syst 17:531–536. https://doi.org/10.1007/s003810100458
Kobayashi T, Tsugawa T, Hatano M, Hashizume C, Mori Y, Shibamoto Y (2015) Gamma knife radiosurgery of craniopharyngioma: results of 30 cases treated at Nagoya Radiosurgery Center. Nagoya J Med Sci 77:447–454
Koutourousiou M, Gardner PA, Fernandez-Miranda JC, Tyler-Kabara EC, Wang EW, Snyderman CH (2013) Endoscopic endonasal surgery for craniopharyngiomas: surgical outcome in 64 patients Clinical article. J Neurosurg 119:1194–1207. https://doi.org/10.3171/2013.6.jns122259
Larkin SJ, Ansorge O (2013) Pathology and pathogenesis of craniopharyngiomas. Pituitary 16:9–17. https://doi.org/10.1007/s11102-012-0418-4
Lee EJ, Cho YH, Hong SH, Kim JH, Kim CJ (2015) Is the complete resection of craniopharyngiomas in adults feasible considering both the oncologic and functional outcomes? J Korean Neurosurg Soc 58:432–441. https://doi.org/10.3340/jkns.2015.58.5.432
Lefranc F, Chevalier C, Vinchon M, Dhellemmes P, Schuring MP, Kaltner H, Brotchi J, Ruchoux MM, Gabius HJ, Salmon I, Kiss R (2003) Characterization of the levels of expression of retinoic acid receptors, galectin-3, macrophage migration inhibiting factor, and p53 in 51 adamantinomatous craniopharyngiomas. J Neurosurg 98:145–153. https://doi.org/10.3171/jns.2003.98.1.0145
Lefranc F, Mijatovic T, Decaestecker C, Kaltner H, Andre S, Brotchi J, Salmon I, Gabius HJ, Kiss R (2005) Monitoring the expression profiles of integrins and adhesion/growth-regulatory galectins in adamantinomatous craniopharyngiomas: their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis. Neurosurgery 56:763–776
Liu H, Liu ZY, Li J, Li Q, You C, Xu JG (2014) Relative quantitative expression of hypoxia-inducible factor 1 alpha messenger ribonucleic acid in recurrent craniopharyngiomas. Neurol India 62:53–56. https://doi.org/10.4103/0028-3886.128291
Liubinas SV, Munshey AS, Kaye AH (2011) Management of recurrent craniopharyngioma. J Clin Neurosci 18:451–457. https://doi.org/10.1016/j.jocn.2010.10.004
Losa M, Vimercati A, Acerno S, Barzaghi RL, Mortini P, Mangili F, Terreni MR, Santambrogio G, Giovanelli M (2004) Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma. J Neurol Neurosurg Psychiatry 75:889–892
Lubansu A, Ruchoux MM, Brotchi J, Salmon I, Kiss R, Lefranc F (2003) Cathepsin B, D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression. Histopathology 43:563–572. https://doi.org/10.1111/j.1365-2559.2003.01751.x
Metzger J, Nachanakian A, Gardeur D, Sichez JP (1979) CT follow-up studies in postoperative craniopharyngiomas. Acta Neurochir Suppl 28:357–361
Minamida Y, Mikami T, Hashi K, Houkin K (2005) Surgical management of the recurrence and regrowth of craniopharyngiomas. J Neurosurg 103:224–232. https://doi.org/10.3171/jns.2005.103.2.0224
Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang LQ, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu SX (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21:2613–2622. https://doi.org/10.1038/sj/onc/1205353
Momota H, Ichimiya S, Ikeda T, Yamaki T, Kikuchi T, Houkin K, Sato N (2003) Immunohistochemical analysis of the p53 family members in human craniopharyngiomas. Brain Tumor Pathol 20:73–77. https://doi.org/10.1007/bf02483450
Mortini P, Gagliardi F, Boari N, Losa M (2013) Surgical strategies and modern therapeutic options in the treatment of craniopharyngiomas. Crit Rev Oncol/Hematol 88:514–529. https://doi.org/10.1016/j.critrevonc.2013.07.013
Muller HL (2014) Craniopharyngioma. Endocr Rev 35:513–543. https://doi.org/10.1210/er.2013-1115
Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758. https://doi.org/10.1038/sj.onc.1207610
Nishi T, Kuratsu J, Takeshima H, Saito Y, Kochi M, Ushio Y (1999) Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma. Int J Mol Med 3:157–161
Papatheodorou H, Papanastasiou AD, Sirinian C, Scopa C, Kalofonos HP, Leotsinidis M, Papadaki H (2014) Expression patterns of SDF1/CXCR4 in human invasive breast carcinoma and adjacent normal stroma: correlation with tumor clinicopathological parameters and patient survival. Pathol Res Pract 210:662–667. https://doi.org/10.1016/j.prp.2014.06.015
Pekmezci M, Louie J, Gupta N, Bloomer MM, Tihan T (2010) Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985–2005. Neurosurgery 67:1341–1349. https://doi.org/10.1227/NEU.0b013e3181f2b583
Prieto R, Pascual JM, Subhi-Issa I, Jorquera M, Yus M, Martinez R (2013) Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence. World Neurosurg 79:733–749. https://doi.org/10.1016/j.wneu.2012.07.033
Qi ST, Lu YT, Pan J, Zhang XA, Long H, Fan J (2011) Anatomic relations of the arachnoidea around the pituitary stalk: relevance for surgical removal of craniopharyngiomas. Acta Neurochir 153:785–796. https://doi.org/10.1007/s00701-010-0940-y
Raghavan R, Dickey WT Jr, Margraf LR, White Iii CL, Coimbra C, Hynan LS, Rushing EJ (2000) Proliferative activity in craniopharyngiomas: clinicopathological correlations in adults and children. Surg Neurol 54:241–248. https://doi.org/10.1016/S0090-3019(00)00298-6
Rodriguez FJ, Scheithauer BW, Tsunoda S, Kovacs K, Vidal S, Piepgras DG (2007) The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 31:1020–1028. https://doi.org/10.1097/PAS.0b013e31802d8a96
Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322. https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
Schweizer L, Capper D, Holsken A, Fahlbusch R, Flitsch J, Buchfelder M, Herold-Mende C, von Deimling A, Buslei R (2015) BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke’s cleft cysts. Neuropathol Appl Neurobiol 41:733–742. https://doi.org/10.1111/nan.12201
Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997–2001
Stache C, Holsken A, Schlaffer SM, Hess A, Metzler M, Frey B, Fahlbusch R, Flitsch J, Buchfelder M, Buslei R (2015) Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathol 25:1–10. https://doi.org/10.1111/bpa.12148
Steno J, Bizik I, Steno A, Matejcik V (2014) Recurrent craniopharyngiomas in children and adults: long-term recurrence rate and management. Acta Neurochir 156:113–122. https://doi.org/10.1007/s00701-013-1938-z
Sun J, Nemoto E, Hong G, Sasaki K (2016) Modulation of stromal cell-derived factor 1 alpha (SDF-1alpha) and its receptor CXCR4 in Porphyromonas gingivalis-induced periodontal inflammation. BMC Oral Health 17:26. https://doi.org/10.1186/s12903-016-0250-8
Szeifert GT, Sipos L, Horvath M, Sarker MH, Major O, Salomvary B, Czirjak S, Balint K, Slowik F, Kolonics L, Pasztor E (1993) Pathological characteristics of surgically removed craniopharyngiomas—analysis of 131 cases. Acta Neurochir 124:139–143. https://doi.org/10.1007/bf01401137
Tavangar SM, Larijani B, Mahta A, Hosseini SM, Mehrazine M, Bandarian F (2004) Craniopharyngioma: a clinicopathological study of 141 cases. Endocr Pathol 15:339–344
Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojorquez D, Morales-Espinosa D, Sotelo J, Arrieta O (2006) Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg 108:661–669. https://doi.org/10.1016/j.clineuro.2006.01.007
Tena-Suck ML, Ortiz-Plata A, Galan F, Sanchez A (2009) Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diagn Pathol 13:82–88. https://doi.org/10.1016/j.anndiagpath.2008.12.004
Thimsen V, Holsken A, Buchfelder M, Flitsch J, Fahlbusch R, Stefanits H, Losa M, Jones DTW, Buslei R (2016) EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke’s cleft cysts. Sci Rep 6:10. https://doi.org/10.1038/srep29731
Ujifuku K, Matsuo T, Takeshita T, Hayashi Y, Hayashi K, Kitagawa N, Hayashi T, Suyama K, Nagata I (2010) Malignant transformation of craniopharyngioma associated with moyamoya syndrome—case report. Neurol Med-Chir 50:599–603
Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, Shiminskimaher T, Flamm ES, Epstein FJ, Miller DC (1994) Craniopharyngiomas—a clinicopathological analysis of factors predictive of recurrence and functional. Neurosurgery 35:1001–1010
Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135. https://doi.org/10.1038/sj.bjc.6602924
Xu JG, Zhang SH, You C, Wang XJ, Zhou Q (2006) Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol 66:30–34. https://doi.org/10.1016/j.surneu.2006.05.047
Yalcin N, Akbulut M, Cagli S, Bir F, Demirtas E (2009) Prognostic significance of the Ki-67 labeling index and P53 protein expression for patient with craniopharyngioma. J Neurol Sci-Turk 26:286–291
Yosef L, Ekkehard KM, Shalom M (2016) Giant craniopharyngiomas in children: short- and long-term implications. Childs Nerv Syst 32:79–88. https://doi.org/10.1007/s00381-015-2961-6
Yu R, Melmed S (2001) Oncogene activation in pituitary tumors. Brain Pathol 11:328–341
Zhu J, You C (2015) Craniopharyngioma: survivin expression and ultrastructure. Oncol Lett 9:75–80. https://doi.org/10.3892/ol.2014.2690
Zygourakis CC, Kaur G, Kunwar S, McDermott MW, Madden M, Oh T, Parsa AT (2014) Modern treatment of 84 newly diagnosed craniopharyngiomas. J Clin Neurosci 21:1558–1566. https://doi.org/10.1016/j.jocn.2014.03.005
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
None required, systematic review of literature. All studies included received ethical approval.
Informed consent
None required, systematic review of literature. All patients in the included previous studies provided informed consent.
Rights and permissions
About this article
Cite this article
Coury, J.R., Davis, B.N., Koumas, C.P. et al. Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review. Neurosurg Rev 43, 41–48 (2020). https://doi.org/10.1007/s10143-018-0978-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10143-018-0978-5